Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
Add more filters










Publication year range
1.
Bioorg Med Chem Lett ; 29(16): 2076-2078, 2019 08 15.
Article in English | MEDLINE | ID: mdl-31300341

ABSTRACT

Mitomycins, produced by several Streptomyces strains, are potent anticancer antibiotics that comprise an aziridine ring fused to a tricyclic mitosane core. Mitomycins have remarkable ability to crosslink DNA with high efficiency. Despite long clinical history of mitomycin C, the biosynthesis of mitomycins, especially mitosane core formation, remains unknown. Here, we report in vitro characterization of three proteins, MmcB (acyl carrier protein), MitE (acyl AMP ligase), and MitB (glycosyltransferase) involved in mitosane core formation. We show that 3-amino-5-hydroxybenzoic acid (AHBA) is first loaded onto MmcB by MitE at the expense of ATP. MitB then catalyzes glycosylation of AHBA-MmcB with uridine diphosphate-N-acetylglucosamine (UDP-GlcNAc) to generate a key intermediate, GlcNAc-AHBA-MmcB, which contains all carbon and nitrogen atoms of the mitosane core. These results provide important insight into mitomycin biosynthesis.


Subject(s)
Acyl Carrier Protein/chemistry , Antibiotics, Antineoplastic/chemistry , Bacterial Proteins/chemistry , Carbon-Sulfur Ligases/chemistry , Glycosyltransferases/chemistry , Mitomycins/biosynthesis , Aminobenzoates/chemistry , Biocatalysis , Hydroxybenzoates/chemistry , Mitomycins/chemistry , Streptomyces/enzymology
3.
J Am Chem Soc ; 129(20): 6470-6, 2007 May 23.
Article in English | MEDLINE | ID: mdl-17461583

ABSTRACT

Mitomycins are bioreductively activated DNA-alkylating agents. One member of this family, mitomycin C, is in clinical use as part of combination therapy for certain solid tumors. The cytotoxicity displayed by mitomycins is dependent on their electrochemical potential which, in turn, is governed in part by the substituents of the quinone moiety. In this paper we describe studies on the biogenesis of the quinone methoxy group present in mitomycins A and B. An engineered Streptomyces lavendulae strain in which the mmcR methyltransferase gene had been deleted failed to produce the three mitomycins (A, B, and C) that are typically isolated from the wild type organism. Analysis of the culture extracts from the mmcR-deletion mutant strain revealed that two new metabolites, 7-demethylmitomycin A and 7-demethylmitomycin B, had accumulated instead. Production of mitomycins A and C or mitomycin B was selectively restored upon supplementing the culture medium of a S. lavendulae strain unable to produce the key precursor 3-amino-5-hydroxybenzoate with either 7-demethylmitomycin A or 7-demethylmitomycin B, respectively. MmcR methyltransferase obtained by cloning and overexpression of the corresponding mmcR gene was shown to catalyze the 7-O-methylation of both C9beta- and C9alpha-configured 7-hydroxymitomycins in vitro. This study provides direct evidence for the catalytic role of MmcR in formation of the 7-OMe group that is characteristic of mitomycins A and B and demonstrates the prerequisite of 7-O-methylation for the production of the clinical agent mitomycin C.


Subject(s)
Mitomycins/biosynthesis , Mitomycins/chemistry , Catalysis , Methylation , Methyltransferases/genetics , Methyltransferases/metabolism , Molecular Structure , Mutation/genetics , Streptomyces/genetics , Streptomyces/metabolism
4.
Oncol Res ; 10(10): 509-21, 1998.
Article in English | MEDLINE | ID: mdl-10338154

ABSTRACT

Treatment of EMT6 mouse mammary tumor cells with [3H]mitomycin C (MC) results in the formation of six major DNA adducts, as described earlier using an HPLC assay of 3H-labeled products of enzymatic hydrolysis of DNA isolated from MC-treated cells. Four of these adducts were identified as monofunctional and bifunctional guanine-N2 adducts in the minor groove of DNA. In order to establish relationships between individual types of MC-DNA adducts and biological responses it is necessary to identify all of the adducts formed in cells. To this end we have now identified a predominant, previously unknown adduct formed in MC-treated EMT6 cells as a derivative not of MC, but of 2,7-diaminomitosene (2,7-DAM), the major bioreductive metabolite of MC. Rigorous proof demonstrates that it is a DNA major groove, guanine-N7 adduct of 2,7-DAM, linked at C-10 to DNA. The adduct is relatively stable at ambient temperature, but is readily depurinated upon heating. Its isolation from MC-treated cells indicates that MC is reductively metabolized to 2,7-DAM, which then undergoes further reductive activation to alkylate DNA, along with the parent MC. Low MC:DNA ratios were identified as a critical factor promoting 2,7-DAM adduct formation in an in vitro model calf thymus DNA/ MC/reductase model system, as well as in MC-treated EMT6 cells. The 2,7-DAM-guanine-N7 DNA adduct appears to be relatively noncytotoxic, as indicated by the dramatically lower cytotoxicity of 2,7-DAM in comparison with MC in EMT6 cells. Like MC, 2,7-DAM exhibited slightly greater cytotoxicity to cells treated under hypoxic as compared to aerobic conditions. However, 2,7-DAM was markedly less cytotoxic than MC under both aerobic and hypoxic conditions. Thus, metabolic reduction of MC to 2,7-DAM represents a detoxification process. The differential effects of MC-DNA and 2,7-DAM-DNA adducts support the concept that specific structural features of the DNA damage may play a critical role in the cytotoxic response to a DNA-targeted chemotherapeutic agent.


Subject(s)
DNA Adducts/biosynthesis , Mitomycin/pharmacology , Mitomycins/biosynthesis , Mitomycins/metabolism , Animals , Chromatography, High Pressure Liquid , DNA Damage , Dose-Response Relationship, Drug , Mammary Neoplasms, Animal , Mice , Nucleic Acid Synthesis Inhibitors/pharmacology , Time Factors , Tumor Cells, Cultured
5.
J Antibiot (Tokyo) ; 39(3): 437-46, 1986 Mar.
Article in English | MEDLINE | ID: mdl-3700245

ABSTRACT

When the normal fermentation medium for the production of mitomycin C with Streptomyces caespitosus is supplemented with a number of primary amines, two new types of mitomycin analogs described as Type I and Type II are produced. Type I analogs are related to mitomycin C with the amine substitution at position C7 on the mitosane ring. Type II analogs also contain the same substitutions at C7 but the conformation of the mitosane ring is related to mitomycin B having an OH at positions C9a and a methyl substituted aziridine. The products obtained from the supplementation of the medium with methylamine, ethylamine, propylamine, propargylamine and 2-methylallylamine were isolated and characterized. In all cases the Type I analogs are more active in a prophage induction test and against L1210 lymphatic leukemia in mice. A number of other amines have been tested and shown to yield new products that have not yet been isolated. No secondary amines are incorporated.


Subject(s)
Mitomycins/biosynthesis , Animals , Chemical Phenomena , Chemistry , Injections, Intraperitoneal , Leukemia L1210/drug therapy , Mice , Mice, Inbred DBA , Mitomycins/therapeutic use , Porfiromycin/biosynthesis , Porfiromycin/therapeutic use , Stereoisomerism
8.
Folia Microbiol (Praha) ; 21(1): 36-42, 1976.
Article in English | MEDLINE | ID: mdl-814067

ABSTRACT

Addition of different concentrations of sodium arsenite to the fermentation medium used for the production of mitomycin antibiotics by Streptomyces caespitosus hindered the biosynthesis of mitomycins and led to the accumulation of 2-oxoglutarate, pyruvate and acetone. Mitomycin C isolated and purified using thin-layer chromatography in low concentration of about 0.1 mug/ml did not affect the RNA, DNA and protein biosynthesis of the growing Bacillus subtilis, while at 10 mug/ml mitomycin C markedly affected RNA, DNA and protein biosynthesis.


Subject(s)
Arsenic/pharmacology , Mitomycins/biosynthesis , Streptomyces/metabolism , Acetone/metabolism , Bacillus subtilis/drug effects , Bacillus subtilis/metabolism , Bacterial Proteins/biosynthesis , DNA, Bacterial/biosynthesis , Fermentation , Ketoglutaric Acids/biosynthesis , Mitomycins/pharmacology , Pyruvates/biosynthesis , RNA, Bacterial/biosynthesis , Streptomyces/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...